Next Article in Journal
Nidulantes of Aspergillus (Formerly Emericella): A Treasure Trove of Chemical Diversity and Biological Activities
Next Article in Special Issue
Changes in Plasma Itaconate Elevation in Early Rheumatoid Arthritis Patients Elucidates Disease Activity Associated Macrophage Activation
Previous Article in Journal
Addressing Glutathione Redox Status in Clinical Samples by Two-Step Alkylation with N-ethylmaleimide Isotopologues
Previous Article in Special Issue
Association of Circulating COMP and YKL-40 as Markers of Metabolic Changes of Cartilage with Adipocytokines in Juvenile Idiopathic Arthritis
Open AccessReview

Metabolomics in Psychiatric Disorders: What We Learn from Animal Models

Department for Psychotherapy and Biopsychosocial Health, Danube University Krems, 3500 Krems, Austria
*
Author to whom correspondence should be addressed.
Metabolites 2020, 10(2), 72; https://doi.org/10.3390/metabo10020072
Received: 8 January 2020 / Revised: 29 January 2020 / Accepted: 10 February 2020 / Published: 17 February 2020
(This article belongs to the Special Issue Metabolomics Analysis for Biomarker Discovery and Human Health)
Biomarkers are a recent research target within biological factors of psychiatric disorders. There is growing evidence for deriving biomarkers within psychiatric disorders in serum or urine samples in humans, however, few studies have investigated this differentiation in brain or cerebral fluid samples in psychiatric disorders. As brain samples from humans are only available at autopsy, animal models are commonly applied to determine the pathogenesis of psychiatric diseases and to test treatment strategies. The aim of this review is to summarize studies on biomarkers in animal models for psychiatric disorders. For depression, anxiety and addiction disorders studies, biomarkers in animal brains are available. Furthermore, several studies have investigated psychiatric medication, e.g., antipsychotics, antidepressants, or mood stabilizers, in animals. The most notable changes in biomarkers in depressed animal models were related to the glutamate-γ-aminobutyric acid-glutamine-cycle. In anxiety models, alterations in amino acid and energy metabolism (i.e., mitochondrial regulation) were observed. Addicted animals showed several biomarkers according to the induced drugs. In summary, animal models provide some direct insights into the cellular metabolites that are produced during psychiatric processes. In addition, the influence on biomarkers due to short- or long-term medication is a noticeable finding. Further studies should combine representative animal models and human studies on cerebral fluid to improve insight into mental disorders and advance the development of novel treatment strategies. View Full-Text
Keywords: animal models; biomarkers; metabolomics; psychiatric disorders animal models; biomarkers; metabolomics; psychiatric disorders
MDPI and ACS Style

Humer, E.; Probst, T.; Pieh, C. Metabolomics in Psychiatric Disorders: What We Learn from Animal Models. Metabolites 2020, 10, 72. https://doi.org/10.3390/metabo10020072

AMA Style

Humer E, Probst T, Pieh C. Metabolomics in Psychiatric Disorders: What We Learn from Animal Models. Metabolites. 2020; 10(2):72. https://doi.org/10.3390/metabo10020072

Chicago/Turabian Style

Humer, Elke; Probst, Thomas; Pieh, Christoph. 2020. "Metabolomics in Psychiatric Disorders: What We Learn from Animal Models" Metabolites 10, no. 2: 72. https://doi.org/10.3390/metabo10020072

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop